FGF19 is considered anticholestatic and hepatoprotective in rodents, and recent clinical studies have shown promising beneficial effects in both patients with nonalcoholic steatohepatitis and primary sclerosing cholangitis treated with an engineered FGF19 analog.31, 32, 33, 34. Here, FGF19 is linked to metabolic dysfunction-associated steatohepatitis.